Determination Total Creatine Kinase Activity and Creatine Kinase Isoenzymes Activities in Patients with Ulcerative Colitis and Crohn’s Disease under Infliximab Therapy

Authors

  • Mustafa S. Al-timimi
  • Yasser A. H. Al-Issa
  • Nawal M. Alkhalidi

DOI:

https://doi.org/10.37506/ijfmt.v15i3.15541

Keywords:

Ulcerative Colitis, Crohn’s Disease, Infliximab therapy, Creatine kinase isoenzymes.

Abstract

Creatine kinase (CK) catalyzes the transfer of a phosphate group from creatine phosphate to adenosine
diphosphate, and the CK has three isoenzymes CK-MM, CK-MB and CK-BB. Ulcerative colitis (UC) and
Crohn’s disease (CD) they are both conditions characterized by long life inflammation of the gastrointestinal
system. The Purpose of this study was to determine the total CK activity and CK isoenzymes in patients
with Crohn’s Disease and Ulcerative Colitis under Infliximab therapy. For the UC patients, CD patients and
controls the CK isoenzyme activities and total CK activity was measured, the three CK isoenzymes separate
by suitable ion-exchanger small columns (DEAE-Sephadex A-50 exchanger). The results display Creatine
kinase isoenzyme chromatograms of all studied groups (UC, CD patients and controls), with variable
activities of (CK-BB) and (CK-MB) isoenzymes with noted an elevation of (CK-MM) isoenzyme activities
and significantly elevation total CK activity in serum of patient groups after therapy when compared with
before therapy patient groups.

Author Biographies

Mustafa S. Al-timimi

Post Graduate ,Department of Chemistry, College of Sciences, University of Baghdad, Iraq

Yasser A. H. Al-Issa

Lect. Dr. Department of Chemistry, College of Sciences, University of Baghdad, Iraq,

Nawal M. Alkhalidi

Prof. Dr. Gastroenterology and Hepatology Teaching Hospital, Baghdad, Iraq

Published

2021-05-17

How to Cite

Al-timimi, M. S. ., Al-Issa, Y. A. H., & Alkhalidi, N. M. . (2021). Determination Total Creatine Kinase Activity and Creatine Kinase Isoenzymes Activities in Patients with Ulcerative Colitis and Crohn’s Disease under Infliximab Therapy. Indian Journal of Forensic Medicine & Toxicology, 15(3), 1633-1638. https://doi.org/10.37506/ijfmt.v15i3.15541